NO20054640D0 - Fremgangsmater for behandling av Parkinsons sykdom - Google Patents

Fremgangsmater for behandling av Parkinsons sykdom

Info

Publication number
NO20054640D0
NO20054640D0 NO20054640A NO20054640A NO20054640D0 NO 20054640 D0 NO20054640 D0 NO 20054640D0 NO 20054640 A NO20054640 A NO 20054640A NO 20054640 A NO20054640 A NO 20054640A NO 20054640 D0 NO20054640 D0 NO 20054640D0
Authority
NO
Norway
Prior art keywords
parkinson
procedures
disease
treatment
Prior art date
Application number
NO20054640A
Other languages
English (en)
Other versions
NO334316B1 (no
NO20054640L (no
Inventor
Luca Benatti
Patricia Salvati
Fariello Ruggero
Carlo Cattaneo
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054640(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of NO20054640D0 publication Critical patent/NO20054640D0/no
Publication of NO20054640L publication Critical patent/NO20054640L/no
Publication of NO334316B1 publication Critical patent/NO334316B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
NO20054640A 2003-04-11 2005-10-10 Anvendelse av safinamid i kombinasjon med levodopa/PDI for fremstilling av medikamenter til behandling av Parkinsons sykdom NO334316B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46220503P 2003-04-11 2003-04-11
PCT/IB2004/001408 WO2004089353A2 (en) 2003-04-11 2004-04-08 Methods for treatment of parkinson's disease

Publications (3)

Publication Number Publication Date
NO20054640D0 true NO20054640D0 (no) 2005-10-10
NO20054640L NO20054640L (no) 2005-12-09
NO334316B1 NO334316B1 (no) 2014-02-03

Family

ID=33159845

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20054640A NO334316B1 (no) 2003-04-11 2005-10-10 Anvendelse av safinamid i kombinasjon med levodopa/PDI for fremstilling av medikamenter til behandling av Parkinsons sykdom
NO20131417A NO335537B1 (no) 2003-04-11 2013-10-28 Anvendelse av safinamid for fremstilling av medikamenter til behandling av Parkinsons sykdom
NO2015018C NO2015018I1 (no) 2003-04-11 2015-07-23 Safinamid for anvendelse i kombinasjon med levodopa/DPI samt eventuelt med andre PD medisinske produkter for behandling av Parkinsons sykdom

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20131417A NO335537B1 (no) 2003-04-11 2013-10-28 Anvendelse av safinamid for fremstilling av medikamenter til behandling av Parkinsons sykdom
NO2015018C NO2015018I1 (no) 2003-04-11 2015-07-23 Safinamid for anvendelse i kombinasjon med levodopa/DPI samt eventuelt med andre PD medisinske produkter for behandling av Parkinsons sykdom

Country Status (27)

Country Link
US (3) US8283380B2 (no)
EP (2) EP1613296B1 (no)
JP (2) JP2006522800A (no)
KR (2) KR101129015B1 (no)
CN (2) CN102274517B (no)
AR (1) AR044007A1 (no)
AT (1) ATE435012T1 (no)
AU (1) AU2004228782B2 (no)
BR (1) BRPI0409364A (no)
CA (1) CA2523188C (no)
CY (3) CY1109295T1 (no)
DE (1) DE602004021790D1 (no)
DK (2) DK1613296T3 (no)
ES (2) ES2326373T3 (no)
HU (1) HUS1500043I1 (no)
IL (2) IL171331A (no)
LU (1) LU92782I2 (no)
MX (1) MXPA05010873A (no)
NL (1) NL300752I2 (no)
NO (3) NO334316B1 (no)
NZ (1) NZ542910A (no)
PL (2) PL2070526T3 (no)
PT (2) PT1613296E (no)
RU (1) RU2342929C2 (no)
SI (2) SI1613296T1 (no)
TW (1) TWI340640B (no)
WO (1) WO2004089353A2 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
PT1423168E (pt) * 2001-09-03 2006-05-31 Newron Pharm Spa Composicao farmaceutica que compreende gabapentina ou um seu analogo e uma x-aminoamida e a sua utilizacao como analgesico
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
DE602004025586D1 (de) * 2003-08-25 2010-04-01 Newron Pharm Spa Alpha-aminoamid derivate zur verwendung als anti-inflammatorische wirkstoffe
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
ES2347581T3 (es) * 2004-09-10 2010-11-02 Newron Pharmaceuticals S.P.A. Uso de (r)-(halobenciloxi)bencilamino-propanamidas como moduladores selectivos del canal de sodio y/o calcio.
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
US8772346B2 (en) 2005-11-09 2014-07-08 Torrent Pharmaceuticals Limited Pharmaceutical composition
AU2006329040C1 (en) * 2005-12-22 2011-12-08 Newron Pharmaceuticals S.P.A. 2 -Phenylethylamino derivatives as calcium and/or sodium channel modulators
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
NZ572798A (en) 2006-06-19 2011-11-25 Newron Pharm Spa Process for the production of safinamide and ralfinamide
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
WO2008129043A1 (en) * 2007-04-24 2008-10-30 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
CN101687773B (zh) * 2007-06-15 2014-07-30 纽朗制药有限公司 取代的2-[2-(苯基)乙氨基]烷酰胺衍生物及其作为钠和/或钙通道调节剂的应用
GB2453770A (en) * 2007-10-19 2009-04-22 Reckitt Benckiser Healthcare Oral composition comprising a cooling agent
WO2009054964A1 (en) * 2007-10-22 2009-04-30 Concert Pharmaceuticals, Inc. Alpha-aminoamide derivatives
EP2229351B1 (en) 2007-12-11 2017-11-08 Newron Pharmaceuticals S.p.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
CN101903021B (zh) * 2007-12-19 2012-11-14 纽朗制药有限公司 用于治疗精神病的α-氨基酰胺衍生物
US20110027354A1 (en) * 2008-04-01 2011-02-03 Kim Hyoung-Chun Anti-parkinsonian compounds
WO2009147432A1 (en) * 2008-06-02 2009-12-10 Generics [Uk] Limited An improved process for the preparation of amines
CA2723869C (en) * 2008-06-02 2013-07-16 Generics [Uk] Limited A process for the preparation of enantiomerically pure amines
PL2303330T5 (pl) * 2008-06-06 2021-10-25 Pharma Two B Ltd. Kompozycje farmaceutyczne do leczenia choroby Parkinsona
CN103893160A (zh) * 2008-06-13 2014-07-02 泰华制药工业有限公司 雷沙吉兰用于改善帕金森氏症
WO2010010138A1 (en) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
CN102048717B (zh) * 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
PT2563355T (pt) 2010-04-27 2016-09-02 Newron Pharm Spa Processo para a produção de sais metanossulfonato de ralfinamida ou dos seus enantiómeros r
KR20120137373A (ko) 2010-04-30 2012-12-20 테이코쿠 팔마 유에스에이, 인코포레이티드 프로필아미노인단 경피 조성물
JP5906302B2 (ja) 2011-03-24 2016-04-20 テイコク ファーマ ユーエスエー インコーポレーテッド 作用剤層および作用剤変換層を含む経皮組成物
US20140227184A1 (en) 2011-08-19 2014-08-14 The Trustees Of Princeton University C-halogen bond formation
US20150031768A1 (en) * 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
CN104797245B (zh) 2012-11-02 2018-05-04 帝国制药美国公司 丙炔基氨基茚满透皮组合物
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
JP2016523918A (ja) 2013-06-27 2016-08-12 シーダーズ−サイナイ メディカル センター 神経変性状態の予防および治療のためのアドレナリン受容体拮抗薬
US20170296498A1 (en) * 2014-04-21 2017-10-19 Civitas Therapeutics, Inc. Rapid Relief of Motor Fluctuations in Parkinson's Disease
CA2963371C (en) 2014-10-02 2020-06-02 Korea Institute Of Science And Technology Alpha-aminoamide derivative compound and pharmaceutical composition containing the same
EP3341380B1 (en) * 2015-08-27 2019-11-13 Prexton Therapeutics SA Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
KR20190016938A (ko) * 2016-03-17 2019-02-19 더 존스 홉킨스 유니버시티 Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법
ITUA20163981A1 (it) 2016-05-31 2017-12-01 Zambon Spa Composizioni farmaceutiche comprendenti safinamide
EP3568082A4 (en) * 2017-01-14 2020-12-09 Neurrx, SPC METHOD OF USING HUMAN EXCREMENTS AND SECRETS FOR THE EARLY DETECTION OF PARKINSON'S DISEASE
CN109251155A (zh) * 2017-07-14 2019-01-22 广东东阳光药业有限公司 α-氨基酰胺衍生物及其用途
WO2019036624A1 (en) * 2017-08-17 2019-02-21 Gu Zi Qiang MONOAMINE PAMOATE SALT TYPE ANTI-PARKINSON AGENTS, PROCESS FOR PREPARING AND USING SAME
BR112020008653A2 (pt) 2017-11-02 2020-10-27 Zambon S.P.A. composições farmacêuticas compreendendo safinamida
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
CN110938014A (zh) * 2019-11-28 2020-03-31 岳千奥 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
WO2021109880A1 (zh) * 2019-12-06 2021-06-10 上海医药集团股份有限公司 药物组合物、成套药盒及其应用
CN110999980A (zh) * 2019-12-19 2020-04-14 新疆石河子职业技术学院（石河子市技工学校） 一种葡萄酒洗浸奶酪加工方法
JP2023538859A (ja) * 2020-08-31 2023-09-12 パーデュー、ファーマ、リミテッド、パートナーシップ レボドパ送達のための組成物及び方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4970200A (en) 1988-03-01 1990-11-13 Schering Aktiengesellschaft Agent for treatment of Parkinson's disease
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en) 1990-12-27 1996-03-26 Relin; Arkadi Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
ATE258067T1 (de) * 1995-05-26 2004-02-15 Pfizer Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) * 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

Also Published As

Publication number Publication date
EP1613296B1 (en) 2009-07-01
ES2326373T3 (es) 2009-10-08
PT2070526E (pt) 2014-03-31
NZ542910A (en) 2007-10-26
IL171331A (en) 2012-03-29
PT1613296E (pt) 2009-07-30
CY1115286T1 (el) 2017-01-04
DE602004021790D1 (de) 2009-08-13
TWI340640B (en) 2011-04-21
WO2004089353A2 (en) 2004-10-21
AU2004228782B2 (en) 2010-05-20
KR101129015B1 (ko) 2012-04-20
DK2070526T3 (da) 2014-03-24
MXPA05010873A (es) 2006-03-21
US20070093495A1 (en) 2007-04-26
US20150150833A1 (en) 2015-06-04
NO334316B1 (no) 2014-02-03
WO2004089353A8 (en) 2005-09-01
HUS1500043I1 (hu) 2018-11-28
NO335537B1 (no) 2014-12-22
RU2342929C2 (ru) 2009-01-10
CY2015025I2 (el) 2016-04-13
CA2523188A1 (en) 2004-10-21
KR20110070929A (ko) 2011-06-24
US8283380B2 (en) 2012-10-09
NO2015018I2 (no) 2015-07-23
SI2070526T1 (sl) 2014-05-30
CN102274517A (zh) 2011-12-14
EP2070526B1 (en) 2014-02-26
DK1613296T3 (da) 2009-10-05
NO20131417L (no) 2005-12-09
PL1613296T3 (pl) 2009-12-31
NO2015018I1 (no) 2015-08-03
CY1109295T1 (el) 2014-07-02
NL300752I2 (no) 2016-07-05
CY2015025I1 (el) 2016-04-13
IL216403A0 (en) 2011-12-29
CA2523188C (en) 2012-09-25
WO2004089353A3 (en) 2004-12-16
TW200505423A (en) 2005-02-16
NO20054640L (no) 2005-12-09
PL2070526T3 (pl) 2014-08-29
IL216403A (en) 2015-01-29
RU2005131422A (ru) 2006-04-27
US20130053368A1 (en) 2013-02-28
CN102274517B (zh) 2018-08-31
US9492410B2 (en) 2016-11-15
ATE435012T1 (de) 2009-07-15
ES2454272T3 (es) 2014-04-10
SI1613296T1 (sl) 2009-10-31
JP2006522800A (ja) 2006-10-05
LU92782I2 (fr) 2015-09-22
JP2013067647A (ja) 2013-04-18
EP1613296A2 (en) 2006-01-11
CN1771030A (zh) 2006-05-10
US8901176B2 (en) 2014-12-02
BRPI0409364A (pt) 2006-04-25
AU2004228782A1 (en) 2004-10-21
KR20060010745A (ko) 2006-02-02
AR044007A1 (es) 2005-08-24
EP2070526A1 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
NO20054640D0 (no) Fremgangsmater for behandling av Parkinsons sykdom
DK1443955T3 (da) PDGF-BB til behandling af Parkinsons sygdom
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
SI1656346T1 (sl) 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
EP1643986A4 (en) PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
NO20034590L (no) Fremgangsmåter for behandling av vaskul¶r sykdom
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
EP1656359A4 (en) MACROCYCLIC BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NO20033804L (no) Karbamatforbindelser for behandling av smerte
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003303141A8 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
AU2003303217A8 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003284898A1 (en) Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
IL172690A0 (en) Methods for the diagnosis and prognosis of alzheimer's disease
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
NO20042166L (no) Kombinasjonsterapi for behandling av sykdom

Legal Events

Date Code Title Description
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: SAFINAMID FOR ANVENDELSE I KOMBINASJON MED LEVODOPA/DPI SAMT EVENTUELT MED ANDRE PD MEDISINSKE PRODUKTER FOR BEHANDLING AV PARKINSONS SYKDOM; EU/1/14/984

Spc suppl protection certif: 2015018

Filing date: 20150723